<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02459353</url>
  </required_header>
  <id_info>
    <org_study_id>ISSDAPA0006</org_study_id>
    <nct_id>NCT02459353</nct_id>
  </id_info>
  <brief_title>Effect of Dapagliflozin on Glycemic Variability</brief_title>
  <acronym>DIVE</acronym>
  <official_title>Effect of Dapagliflozin on Glycemic Variability as an add-on Therapy in Subjects With Type 2 Diabetes Mellitus With in Inadequate Glycemic Control in Insulin: a Multicenter, Placebo-controlled, Double-blind, Randomized Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>The Catholic University of Korea</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>AstraZeneca</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>Severance Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Eulji General Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Kyung Hee University Hospital at Gangdong</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>The Catholic University of Korea</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Dapagliflozin improves glycemic variability in subjects with type 2 diabetes mellitus when
      added to insulin therapy. The primary objective of this study is to assess the effect of
      dapagliflozin on glucose variability compared to placebo after 12 weeks of treatment in type
      2 diabetic patients with inadequate glycemic control on insulin.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This study is a multicenter, randomized, double-blind, placebo-controlled phase 4 study to
      evaluate whether treatment with dapagliflozin add-on to insulin reduces glucose variability
      in type 2 Diabetes Mellitus. The study will recruit type 2 Diabetes Mellitus patients with
      inadequate glucose control on insulin treatment with or without metformin or sulphonylurea.
      It is estimated that 90 type 2 diabetic patients will be enrolled. After randomization, a
      total 12 week treatment of dapagliflozin or matching placebo will be administered. Before and
      after treatment, tests for efficacy and safety outcomes will be performed.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">August 2015</start_date>
  <completion_date type="Actual">May 2017</completion_date>
  <primary_completion_date type="Actual">December 2016</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Glycemic Variability (mean amplitude of glycemic excursion)</measure>
    <time_frame>baseline and 12 weeks</time_frame>
    <description>MAGE(mean amplitude of glycemic excursion)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Glycemic Variability (Coefficient of Variation)</measure>
    <time_frame>baseline and 12 weeks</time_frame>
    <description>CV (Coefficient of Variation)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Glycemic Variability (Standard Deviation)</measure>
    <time_frame>baseline and 12 weeks</time_frame>
    <description>SD (Standard Deviation)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>glycemic control variables HbA1C</measure>
    <time_frame>baseline and each visit(6weeks, 12weeks)</time_frame>
    <description>HbA1C</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>glycemic control variables Fasting Plasma Glucose</measure>
    <time_frame>baseline and each visit(6weeks, 12weeks)</time_frame>
    <description>Fasting Plasma Glucose</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>lipid profile Total cholesterol</measure>
    <time_frame>baseline and each visit(6weeks, 12weeks)</time_frame>
    <description>Total cholesterol</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>lipid profile Triglyceride</measure>
    <time_frame>baseline and each visit(6weeks, 12weeks)</time_frame>
    <description>Triglyceride</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>lipid profile HDL-cholesterol</measure>
    <time_frame>baseline and each visit(6weeks, 12weeks)</time_frame>
    <description>HDL-cholesterol</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>lipid profile LDL-cholesterol</measure>
    <time_frame>baseline and each visit(6weeks, 12weeks)</time_frame>
    <description>LDL-cholesterol</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>glycemic control variables Percentage of patients achieving HbA1c &lt; 7%</measure>
    <time_frame>12weeks</time_frame>
    <description>Percentage of patients achieving HbA1c &lt; 7%</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>glycemic control variables Percentage of patients achieving HbA1c &lt; 6.5%</measure>
    <time_frame>12weeks</time_frame>
    <description>Percentage of patients achieving HbA1c &lt; 6.5%</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>glycemic control variables 24hr urinary glucose excretion</measure>
    <time_frame>baseline and 12weeks</time_frame>
    <description>24hr urinary glucose excretion</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>glycemic control variables Changes in insulin dose</measure>
    <time_frame>baseline and each visit(6weeks, 12weeks)</time_frame>
    <description>Changes in insulin dose</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>blood pressure SBP</measure>
    <time_frame>baseline and each visit(6weeks, 12weeks)</time_frame>
    <description>SBP</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>blood pressure DBP</measure>
    <time_frame>baseline and each visit(6weeks, 12weeks)</time_frame>
    <description>DBP</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">86</enrollment>
  <condition>Type 2 Diabetes Mellitus</condition>
  <arm_group>
    <arm_group_label>dapagliflozin 10mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>a group which treated with dapagliflozin 10mg plus basal insulin therapy</description>
  </arm_group>
  <arm_group>
    <arm_group_label>placebo 10mg</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>a group which treated with dapagliflozin placebo plus basal insulin therapy</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Dapagliflozin</intervention_name>
    <arm_group_label>dapagliflozin 10mg</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <arm_group_label>placebo 10mg</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Female and male aged 20~70 years

          2. Type 2 diabetes patients

          3. Treatment on basal insulin therapy ≥0.2U/kg/day(±metformin and/or ±sulfonylurea) for
             at least 12 weeks

          4. Inadequate glycemic control ; HbA1c 7.0%~10.0% at screening

          5. Female of childbearing potential agrees to routinely use of adequate contraception
             from signing of the informed consent throughout the duration of the study

          6. Understands the study procedure, alternatives, and risks and voluntarily agrees to
             participated by giving written informed consent

        Exclusion Criteria:

          1. Type 1 diabetes(Fasting C-peptide ≤ 0.78ng/dL(or 0.26 nM/L)), secondary diabetes,
             gestational diabetes

          2. Insulin therapy modalities containing short or rapid acting insulin (continuous
             subcutaneous insulin injection, pre-mixed insulin, basal-bolus insulin)

          3. History of diabetic ketoacidosis, hyperglycemic hyperosmolar state

          4. Estimated glomerular filtration rate &lt;60 mL/min/1.73 m2

          5. History of chronic cystitis or recurrent urinary tract infection

          6. Currently on loop diuretics

          7. Adrenal insufficiency, pituitary insufficiency

          8. Currently on medication known to affect glucose metabolism (e.g. corticosteroids,
             immunosuppressants)

          9. Hemoglobin &lt;10g/dL in female, &lt;12g/dL in male

         10. Abnormal liver function (AST/ALT &gt; x3 upper normal limit)

         11. On weight loss program or taking weight loss medication

         12. NYHA class III, IV congestive heart failure

         13. History of acute myocardial infarction, unstable angina, coronary artery bypass graft
             or stroke within 6 months

         14. History of bladder cancer

         15. History of malignancy within 5 years

         16. Pregnant or lactating women

         17. History of excessive alcohol abuse (≥30g/day)

         18. Hypersensitivity to SGLT2 inhibitors

         19. Patient with rare hereditary problems of galactose intolerance, the Lapp lactase
             deficiency or glucose-galactose malabsorption.

         20. Subject who the investigator deems inappropriate to participate in this study
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Kun-Ho Yoon, Ph.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Seoul St. Mary's Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Seoul St.Mary's Hospital</name>
      <address>
        <city>Seoul</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>July 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 26, 2015</study_first_submitted>
  <study_first_submitted_qc>June 1, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 2, 2015</study_first_posted>
  <last_update_submitted>July 12, 2017</last_update_submitted>
  <last_update_submitted_qc>July 12, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">July 13, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>The Catholic University of Korea</investigator_affiliation>
    <investigator_full_name>Kun-Ho Yoon</investigator_full_name>
    <investigator_title>Professor of endocrinology division, Department of Internal Medicine</investigator_title>
  </responsible_party>
  <keyword>dapagliflozin</keyword>
  <keyword>glucose variability</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus</mesh_term>
    <mesh_term>Diabetes Mellitus, Type 2</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Insulin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

